Historical Stock Price
ADHD historical stock prices picture
ADHD (ADHD) has the following price history information. Looking back at ADHD historical stock prices for the last five trading days, on November 09, 2017, ADHD opened at $1.33, traded as high as $1.40 and as low as $1.30, and closed at $1.34. Trading volume was a total of 217.10K shares. On November 10, 2017, ADHD opened at $1.34, traded as high as $1.42 and as low as $1.30, and closed at $1.39. Trading volume was a total of 530.10K shares. On November 13, 2017, ADHD opened at $1.39, traded as high as $1.48 and as low as $1.39, and closed at $1.44. Trading volume was a total of 236.10K shares. On November 14, 2017, ADHD opened at $1.43, traded as high as $1.44 and as low as $1.35, and closed at $1.40. Trading volume was a total of 116.00K shares. On November 15, 2017, ADHD opened at $1.40, traded as high as $1.64 and as low as $1.40, and closed at $1.46. Trading volume was a total of 1.11M shares.

ADHD Historical Stock Prices By Date:

ADHD historical cagr picture

Below, we examine the compound annual growth rate — CAGR for short — of an investment into ADHD shares, starting with a $10,000 purchase of ADHD, and working forward through the historical stock price information to today.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 05/22/2013
End date: 11/15/2017
Start price/share: $7.55
End price/share: $1.46
Dividends collected/share: $0.00
Total return: -80.66%
Average Annual Total Return: -30.66%
Starting investment: $10,000.00
Ending investment: $1,933.69
Years: 4.49
Date Open High Low Close Volume
11/09/2017 $1.33 $1.40 $1.30 $1.34 217.10K
11/10/2017 $1.34 $1.42 $1.30 $1.39 530.10K
11/13/2017 $1.39 $1.48 $1.39 $1.44 236.10K
11/14/2017 $1.43 $1.44 $1.35 $1.40 116.00K
11/15/2017 $1.40 $1.64 $1.40 $1.46 1.11M
Arcturus Therapeutics is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary oral drug candidate, MDX, to treat ADHD and other cognitive dysfunctions including Fragile X Syndrome. The most common available treatments for ADHD are stimulants that increase the brain chemicals dopamine and norepinephrine. Stimulants have significant side effects, and are classified as controlled substances which have significant potential for misuse, abuse and addiction. MDX is not a stimulant, and works with a different mechanism of action. MDX is a proprietary, combined rapid onset release formulation of the chemical Pyridoxine Pyroglutamate.
Date Close
11/09/2017$1.34
11/10/2017$1.39
11/13/2017$1.44
11/14/2017$1.40
11/15/2017$1.46
ADHD is categorized under the Healthcare sector; below are some other companies in the same sector:

ADK Historical Stock Prices
ADMA Historical Stock Prices
ADMP Historical Stock Prices
ADMS Historical Stock Prices
ADPT Historical Stock Prices
ADRO Historical Stock Prices
ADUS Historical Stock Prices
ADVM Historical Stock Prices
ADXS Historical Stock Prices
AEGR Historical Stock Prices


ADHD Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2020, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.